{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=hCG&page=2",
    "query": {
      "intervention": "hCG",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=hCG&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-18T19:06:09.489Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07129473",
      "title": "Hyperemesis Gravidarum Risk Reduction With Metformin",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hyperemesis Gravidarum"
      ],
      "interventions": [
        {
          "name": "Metformin Extended Release Oral Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 49 Years · Female only"
      },
      "enrollment_count": 224,
      "start_date": "2026-07-13",
      "completion_date": "2031-03",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-09-18T19:06:09.489Z",
      "location_count": 2,
      "location_summary": "Birmingham, Alabama • Los Angeles, California",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07129473"
    },
    {
      "nct_id": "NCT01009723",
      "title": "Preterm Delivery Risk Prediction by Measurement of Prenatal Serum Screening Markers",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Preterm Delivery"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Esoterix Genetic Laboratories, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 2000,
      "start_date": "2010-03",
      "completion_date": "2012-07",
      "has_results": false,
      "last_update_posted_date": "2012-06-08",
      "last_synced_at": "2026-09-18T19:06:09.489Z",
      "location_count": 2,
      "location_summary": "Westborough, Massachusetts • Santa Fe, New Mexico",
      "locations": [
        {
          "city": "Westborough",
          "state": "Massachusetts"
        },
        {
          "city": "Santa Fe",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01009723"
    },
    {
      "nct_id": "NCT02759887",
      "title": "Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Down Syndrome",
        "Alzheimer's Dementia"
      ],
      "interventions": [
        {
          "name": "biospecimen collection",
          "type": "PROCEDURE"
        },
        {
          "name": "cognitive assessments",
          "type": "OTHER"
        },
        {
          "name": "caregiver questionnaire",
          "type": "OTHER"
        },
        {
          "name": "Florbetapir F18 imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "MRI",
          "type": "PROCEDURE"
        },
        {
          "name": "Fludeoxyglucose F18 (FDG)",
          "type": "PROCEDURE"
        },
        {
          "name": "Tau Pet",
          "type": "PROCEDURE"
        },
        {
          "name": "Actigraphy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "St. Joseph's Hospital and Medical Center, Phoenix",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2016-11",
      "completion_date": "2018-12",
      "has_results": false,
      "last_update_posted_date": "2019-10-29",
      "last_synced_at": "2026-09-18T19:06:09.489Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02759887"
    },
    {
      "nct_id": "NCT00042952",
      "title": "Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Dysgerminoma",
        "Recurrent Malignant Testicular Germ Cell Tumor",
        "Recurrent Ovarian Germ Cell Tumor",
        "Stage II Malignant Testicular Germ Cell Tumor",
        "Stage II Ovarian Germ Cell Tumor",
        "Stage III Malignant Testicular Germ Cell Tumor",
        "Stage III Ovarian Germ Cell Tumor",
        "Testicular Seminoma"
      ],
      "interventions": [
        {
          "name": "imatinib mesylate",
          "type": "DRUG"
        },
        {
          "name": "therapeutic conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2002-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-17",
      "last_synced_at": "2026-09-18T19:06:09.489Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00042952"
    },
    {
      "nct_id": "NCT00709462",
      "title": "A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Colorectal Cancer",
        "Pancreatic Cancer",
        "Bladder Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "CDX1307",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Celldex Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2004-03",
      "completion_date": "2010-06",
      "has_results": false,
      "last_update_posted_date": "2010-07-26",
      "last_synced_at": "2026-09-18T19:06:09.489Z",
      "location_count": 3,
      "location_summary": "Detroit, Michigan • Durham, North Carolina • Huntersville, North Carolina",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Huntersville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00709462"
    },
    {
      "nct_id": "NCT01042704",
      "title": "Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myeloma"
      ],
      "interventions": [
        {
          "name": "Bendamustine",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Aspirin",
          "type": "DRUG"
        },
        {
          "name": "Prophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Antibiotic",
          "type": "DRUG"
        },
        {
          "name": "Biweekly Follow Up",
          "type": "OTHER"
        },
        {
          "name": "Cyclical Follow Up",
          "type": "OTHER"
        },
        {
          "name": "Restaging",
          "type": "OTHER"
        },
        {
          "name": "Post-Treatment Follow Up",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Robert Redner, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2008-02",
      "completion_date": "2015-03",
      "has_results": false,
      "last_update_posted_date": "2017-07-31",
      "last_synced_at": "2026-09-18T19:06:09.489Z",
      "location_count": 22,
      "location_summary": "Detroit, Michigan • Steubenville, Ohio • Beaver, Pennsylvania + 13 more",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Steubenville",
          "state": "Ohio"
        },
        {
          "city": "Beaver",
          "state": "Pennsylvania"
        },
        {
          "city": "Clairton",
          "state": "Pennsylvania"
        },
        {
          "city": "Greensburg",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01042704"
    },
    {
      "nct_id": "NCT00505752",
      "title": "Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infertility"
      ],
      "interventions": [
        {
          "name": "AS900672-Enriched 50 microgram (mcg)",
          "type": "DRUG"
        },
        {
          "name": "AS900672-Enriched 100 mcg",
          "type": "DRUG"
        },
        {
          "name": "AS900672-Enriched 150 mcg",
          "type": "DRUG"
        },
        {
          "name": "Follitropin alfa 150 international unit (IU)",
          "type": "DRUG"
        },
        {
          "name": "Recombinant human chorionic gonadotropin (r-hCG)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck KGaA, Darmstadt, Germany",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "36 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 36 Years · Female only"
      },
      "enrollment_count": 520,
      "start_date": "2007-01",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2014-02-13",
      "last_synced_at": "2026-09-18T19:06:09.489Z",
      "location_count": 1,
      "location_summary": "Rockland, Massachusetts",
      "locations": [
        {
          "city": "Rockland",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00505752"
    },
    {
      "nct_id": "NCT06074055",
      "title": "PRogrammed Versus Modified Natural Cycle After Euploid Failed Embryo Transfer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Infertility, Female"
      ],
      "interventions": [
        {
          "name": "FET Protocol",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Reproductive Medicine Associates of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "53 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 53 Years · Female only"
      },
      "enrollment_count": 9,
      "start_date": "2023-10-25",
      "completion_date": "2024-10-21",
      "has_results": false,
      "last_update_posted_date": "2025-02-07",
      "last_synced_at": "2026-09-18T19:06:09.489Z",
      "location_count": 2,
      "location_summary": "Basking Ridge, New Jersey • Marlton, New Jersey",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Marlton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06074055"
    },
    {
      "nct_id": "NCT00938314",
      "title": "Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stroke"
      ],
      "interventions": [
        {
          "name": "human chorionic gonadotropin (hCG), then epoetin alfa (EPO)",
          "type": "DRUG"
        },
        {
          "name": "Saline Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stem Cell Therapeutics Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 96,
      "start_date": "2009-08",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2011-11-29",
      "last_synced_at": "2026-09-18T19:06:09.489Z",
      "location_count": 1,
      "location_summary": "Orange, California",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00938314"
    },
    {
      "nct_id": "NCT01687712",
      "title": "Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infertility"
      ],
      "interventions": [
        {
          "name": "AFOLIA",
          "type": "DRUG"
        },
        {
          "name": "Gonal-f® RFF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fertility Biotech AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "42 Years",
        "sex": "FEMALE",
        "summary": "35 Years to 42 Years · Female only"
      },
      "enrollment_count": 1100,
      "start_date": "2013-11-25",
      "completion_date": "2016-11-14",
      "has_results": true,
      "last_update_posted_date": "2017-12-05",
      "last_synced_at": "2026-09-18T19:06:09.489Z",
      "location_count": 22,
      "location_summary": "Tempe, Arizona • Encino, California • Newark, Delaware + 18 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01687712"
    }
  ]
}